Total Voting Rights

RNS Number : 2239U

Ergomed plc

01 April 2021

 

 PRESS RELEASE

Total Voting Rights

Guildford, UK - 1 April 2021: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 31 March 2021 consisted of 48,749,581 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Angela Gray	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

 

END

 

 

TVRJBMBTMTIJTIB